Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.

Getting the merger over the line will be a relief to the pharma ... Analysts said the addition of the drugs would help support Amgen’s “maturing” product portfolio while it works on bringing ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Weight-loss drug developers line up to tap market worth $150 billion Healthcare & Pharmaceuticalscategory· December 20, 2024 Amgen's leukemia drug Blincyto infringes patents owned by Germany's ...

Analysts have previously suggested that Lumakras could become a $1 billion-plus product if Amgen can extend the label for the drug into the first-line NSCLC setting and also get approval for the ...

On Monday, Nov. 26, Amgen announced top-line results from a phase 2 trial ... In the third quarter, 10 of the company's products grew sales by a double-digit percentage year over year.

Amgen (Thousand Oaks, CA) has won its US district court patent battle against Transkaryotic Therapies (TKT; Cambridge, MA) and Aventis Pharmaceuticals (Bridgewater, NJ) over its multi-billion ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...